Atara Biotherapeutics, Inc. (ATRA)

Trade ATRA now with
3/9/2017 8:17:52 AM Atara Biotherapeutics Q4 Net Loss $18.2 Mln Or $0.63/shr Vs. Loss $21.2 Mln Or $0.75/shr Prior Year
1/3/2017 8:07:24 AM Atara Bio Concludes EMA Scientific Advice And Plans To Submit Conditional MAA In Europe For Allogeneic EBV
12/12/2016 8:08:46 AM Atara Bio Reaches Agreement With FDA On Design Of Phase 3 Trials For Its Lead Anti-Cancer Immunotherapy Program
11/4/2016 8:11:45 AM Atara Biotherapeutics Q3 Net Loss $25.4 Mln Or $0.88/shr Vs. Net Loss $11.9 Mln Or $0.43/shr Last Year
10/18/2016 8:08:12 AM Atara Bio Granted Access To Priority Medicines Regulatory Support For Allogeneic Epstein-Barr Virus
10/11/2016 8:10:32 AM Atara Bio Gets Positive Opinion From EMA On Orphan Drug Designation For CMV-CTL Product Candidate
7/12/2016 8:17:32 AM Atara Bio Doses First Patient In Multi-Center Expanded Access Protocol For Study Of Allogeneic EBV-CTLs
6/23/2016 9:35:33 AM Atara Gets Advanced Therapy Medicinal Product Classification For Allogeneic EBV-CTLs From EMA
3/23/2016 9:16:31 AM Atara Bio Gets EMA Orphan Drug Designation For Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes
3/4/2016 10:33:54 AM Canaccord Is Lowering Atara Biotherapeutics, Inc. (ATRA) 2016 Estimate To -2.42 From -2.18
2/8/2016 8:07:26 AM Atara Bio Gets FDA Orphan Drug Designation For EBV-CTL To Treat EBV-PTLD
12/15/2015 8:17:13 AM Canaccord Is Raising Atara Biotherapeutics, Inc. (ATRA) 2016 Estimate To -2.18 From -3.67